Last updated on September 2010

Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis


Brief description of study

The overall purpose of this one year extension is to allow further treatment of patients who have already completed the core study, and to enable collection of long term efficacy and safety data. Patients will continue to receive Exjade at the dose they received at the end of the core study.

Clinical Study Identifier: NCT01199003

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Shimotsuga-gun, Japan
1.85miles
  Connect »